Sevelamer Medical Valley (Sevelamer Carbonate)
Non-calcium, non-metal phosphate binder for the control of hyperphosphatemia in adults with chronic kidney disease
Quick Facts About Sevelamer Medical Valley
Key Takeaways About Sevelamer Medical Valley
- Take with meals: Sevelamer must be taken with food so it can bind dietary phosphate in the gastrointestinal tract – taking it on an empty stomach has almost no effect
- Non-calcium advantage: Unlike calcium-based binders, sevelamer does not add calcium load and may lower the risk of vascular calcification in dialysis patients
- Lowers LDL cholesterol: Sevelamer also binds bile acids, typically reducing LDL cholesterol by 15–30% – a secondary cardiovascular benefit
- Gastrointestinal effects are common: Nausea, constipation, diarrhoea, and abdominal discomfort are frequent but usually mild; severe bowel complications are rare but require immediate attention
- Swallow tablets whole: Do not crush, chew, or break the tablets – they can expand in water and may cause choking or throat irritation if not swallowed intact
What Is Sevelamer Medical Valley and What Is It Used For?
Sevelamer Medical Valley (sevelamer carbonate) is a phosphate binder used to lower high phosphate levels in the blood of adults with chronic kidney disease (CKD). It is prescribed for patients on haemodialysis or peritoneal dialysis, and for patients with CKD not yet on dialysis when serum phosphate is 1.78 mmol/L (5.5 mg/dL) or higher. It works in the gut by trapping dietary phosphate so it is excreted rather than absorbed.
Sevelamer Medical Valley 800 mg film-coated tablets contain sevelamer carbonate as the active substance. Sevelamer is a non-absorbed, cross-linked polyamine polymer. Because it is not absorbed from the gastrointestinal tract, it does not enter the bloodstream and exerts its effect entirely within the digestive lumen. This is a fundamental difference between sevelamer and most other prescription medications, and it explains both its favourable systemic safety profile and its unique pattern of side effects.
The healthy human kidneys filter around 180 litres of plasma each day and excrete excess phosphate. When kidney function declines – especially in chronic kidney disease stages 4 and 5 – the kidneys can no longer eliminate enough phosphate. Phosphate accumulates in the blood, a condition called hyperphosphatemia. Persistently high phosphate drives a cascade of complications known collectively as CKD-mineral and bone disorder (CKD-MBD), including secondary hyperparathyroidism, renal osteodystrophy (bone disease), calcification of arteries and heart valves, intractable itching (pruritus), and increased cardiovascular mortality. Controlling serum phosphate is therefore one of the central goals of managing advanced CKD.
Sevelamer works by binding phosphate ions in the gut through ionic and hydrogen bonding with its multiple amine groups. When taken with meals, the polymer traps dietary phosphate before it can be absorbed into the blood, and the bound phosphate is eliminated in the stools. In clinical studies, sevelamer lowers serum phosphate by approximately 0.6–0.9 mmol/L (1.8–2.8 mg/dL) from baseline in dialysis patients, with most of the reduction seen within 2–4 weeks of starting treatment or after a dose change.
Beyond phosphate control, sevelamer has pharmacological properties that distinguish it from older phosphate binders. It binds bile acids in the gut, interrupting their enterohepatic recirculation, which increases hepatic LDL-receptor activity and typically lowers LDL cholesterol by 15–30%. It has also been shown to reduce serum uric acid and to modestly lower inflammatory markers such as C-reactive protein. Unlike calcium-based binders (calcium carbonate, calcium acetate), sevelamer does not contribute to calcium load, which is important because positive calcium balance is linked to progression of vascular calcification in dialysis patients.
Sevelamer Medical Valley is indicated in adults aged 18 years and older. Its use in children and adolescents is generally reserved for specialist paediatric nephrology settings using the reference brands where paediatric data exist. It is not an appropriate treatment for hyperphosphatemia caused by acute, transient conditions such as tumour lysis syndrome in haematology patients – for those indications, other agents and intravenous management are used.
According to the KDIGO 2017 Clinical Practice Guideline Update for CKD-MBD, treatment decisions for elevated phosphate in CKD are based on serial serum phosphate measurements interpreted together with calcium and parathyroid hormone (PTH). Dietary phosphate restriction is usually the first step. When medication is needed, sevelamer is considered alongside other non-calcium binders (such as lanthanum carbonate and iron-based binders). KDIGO recommends restricting the dose of calcium-based binders in adults receiving phosphate-lowering therapy, because of accumulating evidence linking positive calcium balance to vascular calcification. This has positioned sevelamer as a widely used option in modern dialysis practice.
What Should You Know Before Taking Sevelamer Medical Valley?
Do not take Sevelamer Medical Valley if you are allergic to sevelamer or any of the tablet ingredients, or if you have low phosphate in the blood (hypophosphatemia) or a blocked bowel. Use with caution if you have swallowing problems, severe gastrointestinal motility disorders, inflammatory bowel disease, or have had major gastrointestinal surgery. Tell your doctor about all other medicines you take, as sevelamer can reduce the absorption of several drugs.
Contraindications
You must not take Sevelamer Medical Valley if any of the following applies to you:
- You are allergic (hypersensitive) to sevelamer carbonate or to any of the other ingredients of this medicine
- You have low blood phosphate levels (hypophosphatemia) – sevelamer would lower phosphate further and could cause harm
- You have bowel obstruction (intestinal obstruction) or a blocked bowel
If you are uncertain whether any of these applies to you, discuss this with your doctor or pharmacist before taking your first dose.
Warnings and Precautions
Talk to your doctor before taking Sevelamer Medical Valley if any of the following apply to you:
- You have difficulty swallowing (dysphagia) or swallowing disorders. Rare cases of tablets lodging in the oesophagus have been reported. Always take the tablets whole with a full glass of water.
- You have severe gastrointestinal motility disorders, including severe gastroparesis, retained gastric contents, abnormal or irregular bowel motility, or active inflammatory bowel disease (Crohn's disease or ulcerative colitis)
- You have had major gastrointestinal surgery
- You have low levels of fat-soluble vitamins (A, D, E, K) or folic acid – sevelamer may reduce their absorption and your doctor may recommend supplementation
- You have been told you have metabolic acidosis, which is common in CKD and which sevelamer carbonate may partially correct (an advantage over the older sevelamer hydrochloride)
- You are at risk of peritonitis during peritoneal dialysis – dialysis-related infections should be recognised and treated promptly
Very rare but serious gastrointestinal events have been reported with sevelamer, including intestinal obstruction, ileus, subileus, gastrointestinal perforation, and gastrointestinal bleeding. Stop taking sevelamer and seek immediate medical attention if you develop severe abdominal pain, persistent vomiting, inability to pass stools or gas, black or bloody stools, or new severe constipation.
Cases of crystal deposition in the bowel wall associated with sevelamer have also been described in histological studies, particularly in patients with pre-existing gastrointestinal disease. If you experience unexplained gastrointestinal symptoms, tell the physician performing any endoscopy or surgery that you are taking sevelamer.
Monitoring during treatment: Your nephrologist will regularly check your serum phosphate, calcium, bicarbonate, and PTH levels – typically every 1–3 months in dialysis patients. Calcium supplementation may sometimes be required separately if your blood calcium falls too low, because sevelamer itself contains no calcium. Vitamin D status should also be monitored.
Pregnancy and Breastfeeding
There is no adequate data on the use of sevelamer in pregnant women. Because sevelamer can reduce absorption of several vitamins, it is not recommended during pregnancy unless the benefits clearly outweigh the potential risks. If sevelamer is used during pregnancy, vitamin supplementation (including fat-soluble vitamins and folic acid) should be considered.
Sevelamer is not absorbed from the gastrointestinal tract and is therefore unlikely to pass into breast milk in clinically relevant amounts. Breastfeeding is generally considered compatible with sevelamer, but this should be discussed with your doctor based on your individual situation.
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor for advice before taking this medicine.
Driving and Operating Machinery
Sevelamer has no or negligible influence on the ability to drive and use machines. However, the underlying chronic kidney disease and associated conditions (anaemia, uraemia, dialysis fatigue) may affect alertness, and you should be guided by how you feel.
How Does Sevelamer Medical Valley Interact with Other Drugs?
Sevelamer can reduce the absorption of several important medicines by binding them in the gut, including ciprofloxacin, levothyroxine, ciclosporin, tacrolimus, mycophenolate mofetil, and some oral anticoagulants. To avoid this, take these medicines at least 1 hour before or 3 hours after sevelamer, and monitor drug levels where appropriate. Always inform your healthcare team about every medication, vitamin, and herbal product you use.
Because sevelamer is not absorbed, it does not cause the type of systemic pharmacokinetic interactions seen with many prescription drugs. Instead, its primary interaction mechanism is binding of other drugs in the gastrointestinal tract, which can reduce their bioavailability. This is clinically important for a number of medicines with a narrow therapeutic window.
Major Interactions
Based on pharmacokinetic studies and post-marketing experience, particular caution is required with the following medicines:
| Drug | Interaction | Severity | Clinical Advice |
|---|---|---|---|
| Ciprofloxacin | Sevelamer reduced ciprofloxacin bioavailability by approximately 50% in co-administration studies, risking therapeutic failure of antibiotic therapy. | Major | Take ciprofloxacin at least 1 hour before or 3 hours after sevelamer. |
| Ciclosporin, tacrolimus | Reduced blood levels of these immunosuppressants have been reported in transplant patients receiving sevelamer, with risk of subtherapeutic exposure and graft rejection. | Major | Increase frequency of blood level monitoring. Separate administration by 1 hour before or 3 hours after sevelamer. |
| Mycophenolate mofetil | Sevelamer may reduce mycophenolic acid exposure in transplant recipients. | Moderate | Separate dosing and monitor clinical response. |
| Levothyroxine | Case reports of hypothyroidism due to reduced levothyroxine absorption when co-administered with sevelamer. | Moderate | Take levothyroxine on an empty stomach at least 1 hour before sevelamer. Monitor TSH more closely. |
| Antiepileptics (e.g. phenytoin), antiarrhythmics | Theoretical risk of reduced absorption; clinical relevance individually variable. | Moderate | Monitor clinical effect and drug levels where available. Separate administration by at least 1 hour. |
| Proton pump inhibitors (PPIs) | PPIs have been reported to further increase serum phosphate and may attenuate the response to sevelamer in some patients. | Moderate | No dose adjustment generally required, but consider if phosphate response is unexpectedly poor. |
| Oral anticoagulants (warfarin) | Possible reduction in vitamin K absorption with prolonged use; isolated reports of altered INR. | Moderate | Continue routine INR monitoring; unusual INR changes should prompt review of timing and vitamin K status. |
Minor Interactions
In controlled pharmacokinetic studies, no clinically significant interactions have been demonstrated with digoxin, warfarin (short-term), enalapril, metoprolol, iron (ferrous sulfate), or metformin. Calcium-based supplements, phosphate-containing laxatives, and oral nutritional supplements should still be reviewed carefully in the context of CKD-MBD management, but they do not typically alter sevelamer efficacy.
For any medicine not listed here, a reasonable general rule in patients taking sevelamer is to separate administration by at least 1 hour before or 3 hours after if the medicine has a narrow therapeutic window or if its therapeutic effect appears diminished. Always tell every healthcare professional involved in your care – including dentists, surgeons, and pharmacists – that you are taking sevelamer.
What Is the Correct Dosage of Sevelamer Medical Valley?
The typical starting dose for adults is 2.4–4.8 g (3–6 tablets of 800 mg) per day divided between meals, depending on baseline serum phosphate. The dose is then titrated every 2–4 weeks to achieve target phosphate levels (around 1.13–1.78 mmol/L in dialysis patients). Tablets must be swallowed whole with meals. Do not crush, chew, or break them.
Always take Sevelamer Medical Valley exactly as your doctor has told you. Check with your doctor or pharmacist if you are unsure. Dosing is individualised to each patient's serum phosphate level, dietary phosphate intake, and tolerability.
Adults
Sevelamer Medical Valley is available only as 800 mg film-coated tablets. Lower strengths of sevelamer carbonate (as oral powder sachets) exist under reference brand names for patients who cannot take tablets, but tablets are the standard adult formulation.
Recommended Starting Dose (Adults Not Previously on a Phosphate Binder)
- Serum phosphate 1.78–2.42 mmol/L (5.5–7.5 mg/dL): 1 tablet (800 mg) three times daily with meals – total 2.4 g/day
- Serum phosphate 2.42–2.91 mmol/L (7.5–9.0 mg/dL): 2 tablets (1.6 g) three times daily with meals – total 4.8 g/day
- Serum phosphate >2.91 mmol/L (>9.0 mg/dL): 2 tablets (1.6 g) three times daily with meals; may be increased to 3 tablets (2.4 g) three times daily – total up to 7.2 g/day
Switching from Calcium Acetate or Sevelamer Hydrochloride
- From calcium acetate: use approximately a gram-for-gram equivalent of sevelamer carbonate as starting dose (1 g calcium acetate ≈ 800 mg sevelamer carbonate)
- From sevelamer hydrochloride: switch on a 1:1 mg basis (same total daily dose and dosing schedule)
- Monitor serum phosphate closely after switching and titrate as required
Dose Titration (Every 2–4 Weeks)
- Increase by 400–800 mg per meal (i.e. half a tablet to one tablet per meal) if phosphate remains above target
- Decrease the dose or temporarily stop treatment if phosphate falls below 1.13 mmol/L (3.5 mg/dL)
- Typical maintenance dose in dialysis patients: 6–9 tablets per day (4.8–7.2 g) in divided doses with meals
- Maximum studied dose: 14 g/day of sevelamer hydrochloride (approximately equivalent to 14 g/day sevelamer carbonate)
How to Take the Tablets
- Always take with meals. Taking sevelamer on an empty stomach removes its phosphate-binding effect. Split the total daily dose across your main meals of the day.
- Swallow whole with water. Do not crush, chew, break, or dissolve the tablets. The polymer can expand in water and tablets that are broken or chewed may cause oesophageal irritation or choking.
- If a meal is skipped, skip the dose for that meal and take the next dose at your next meal. Do not double up.
- Many patients find it easier to take the tablets in the middle or end of the meal rather than all at once at the start, which can reduce the feeling of fullness.
Children and Adolescents
The Sevelamer Medical Valley 800 mg tablet formulation is not recommended for children and adolescents under 18 years of age. Paediatric nephrology specialists may prescribe sevelamer carbonate in dedicated paediatric presentations (oral powder) where needed, based on body surface area and serum phosphate. This should only be done in specialist centres with close mineral metabolism monitoring.
Elderly Patients
No specific dose adjustment is required based on age alone. However, older patients with CKD often have more comorbidities, polypharmacy, and a higher risk of drug interactions, so careful review of all co-prescribed medicines and more frequent laboratory monitoring may be appropriate.
Missed Dose
If you miss a dose with a meal, skip the missed dose and take the next dose at your next meal. Do not take a double dose to make up for a missed one. Taking sevelamer between meals will not compensate for the missed dose because there is no dietary phosphate in the gut for it to bind.
Overdose
Sevelamer has been given at daily doses of up to 14 g per day for up to one year to dialysis patients without evidence of systemic toxicity, because the drug is not absorbed. However, an excessive dose may cause gastrointestinal symptoms and, in theory, excessively low serum phosphate. If you accidentally take a much higher dose than prescribed, contact your doctor, pharmacist, or nearest emergency department for advice.
Hyperphosphatemia in advanced CKD is typically a chronic, lifelong condition. If you stop taking sevelamer without adjusting other treatment, serum phosphate will usually rise again within days. Over months, this contributes to worsening bone disease, vascular calcification, and higher cardiovascular risk. Always discuss any planned change with your nephrology team.
What Are the Side Effects of Sevelamer Medical Valley?
The most common side effects are gastrointestinal: nausea, vomiting, constipation, diarrhoea, indigestion, flatulence, and abdominal pain. These affect more than 1 in 10 patients but are usually mild and often improve with time. Rare but serious side effects include intestinal obstruction, gastrointestinal perforation, and severe hypersensitivity reactions – seek urgent medical care if these occur.
Like all medicines, Sevelamer Medical Valley can cause side effects, although not everyone gets them. Because sevelamer is not absorbed from the gut, almost all of its adverse effects are concentrated in the gastrointestinal tract. Systemic effects are uncommon compared with most prescription medicines.
Very Common Side Effects
- Nausea
- Vomiting
- Upper abdominal pain
- Constipation
Common Side Effects
- Diarrhoea
- Indigestion (dyspepsia)
- Flatulence (wind)
- Abdominal pain
- Headache
- Low blood pressure (hypotension) or high blood pressure (hypertension) – related to underlying CKD
- Pruritus (itching) and rash
- Metabolic acidosis or alkalosis
Uncommon Side Effects
- Hypersensitivity reactions
- Low vitamin K-dependent clotting factor levels (prolonged prothrombin time)
- Low levels of folic acid and fat-soluble vitamins (A, D, E, K) with long-term use
- Drowsiness or general fatigue unrelated to dialysis
Rare and Very Rare Side Effects
- Intestinal obstruction and ileus / subileus – presenting with severe abdominal pain, distension, vomiting, and inability to pass stools or gas
- Gastrointestinal perforation – a surgical emergency
- Gastrointestinal bleeding and ulceration; rarely colitis associated with crystal deposition in the bowel wall
- Oesophageal tablet retention leading to dysphagia or chest discomfort – particularly if tablets are not swallowed whole with enough water
- Severe hypersensitivity reactions with rash, swelling, or difficulty breathing
- Dental deposits and tooth discolouration with very long-term use (rare post-marketing reports)
- Pancreatitis (isolated post-marketing reports)
- Severe abdominal pain, persistent vomiting, or inability to pass stools or gas
- Black, tarry, or bloody stools
- Chest pain or a feeling that a tablet has lodged in your throat or chest
- Swelling of the face, lips, tongue, or throat, or difficulty breathing
- Severe skin rash with blistering or peeling
- Unusual bruising or bleeding that may suggest low clotting factors
Most gastrointestinal side effects are dose-related and transient, improving during the first weeks of treatment or after dose reduction. Taking the tablets with meals (rather than between meals), ensuring adequate fluid intake, and dividing larger doses across several meals often reduces symptoms. Your nephrologist may also recommend dietary or lifestyle adjustments &ndash ensuring enough fibre, staying physically active where possible, and avoiding additional constipating medicines – to minimise bowel-related adverse effects.
How Should You Store Sevelamer Medical Valley?
Store Sevelamer Medical Valley below 25°C (77°F) in the original container to protect it from moisture. Keep the bottle or blister pack tightly closed. Keep out of the sight and reach of children. Do not use after the expiry date printed on the carton and do not flush unused tablets down the drain – return them to your pharmacy.
Keep this medicine out of the sight and reach of children. Do not use Sevelamer Medical Valley after the expiry date stated on the carton, bottle label, or blister foil after “EXP”. The expiry date refers to the last day of that month.
The recommended storage conditions are below 25°C (77°F). Store in the original container (bottle or blister pack) and keep the container tightly closed to protect the tablets from moisture. Sevelamer is hygroscopic – it can absorb moisture from the air – which can degrade the tablets over time if they are not stored properly.
Do not dispose of any medicines via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help protect the environment and prevent accidental exposure of other people.
What Does Sevelamer Medical Valley Contain?
Each Sevelamer Medical Valley 800 mg film-coated tablet contains 800 mg of sevelamer carbonate as the active ingredient. Inactive ingredients typically include microcrystalline cellulose, sodium chloride, zinc stearate, and a film coating made of hypromellose, diacetylated monoglycerides, iron oxides, and titanium dioxide (E171). Always check the patient information leaflet of the specific pack for the full list of excipients.
Active Ingredient
Each film-coated tablet contains 800 mg of sevelamer carbonate. Sevelamer carbonate is the carbonate salt form of the sevelamer polymer. Compared to the older sevelamer hydrochloride, sevelamer carbonate has the advantage of not contributing to metabolic acidosis – in fact, it can modestly improve bicarbonate levels, which is frequently beneficial in CKD.
Inactive Ingredients (Excipients)
Tablet core (typical): microcrystalline cellulose, sodium chloride, zinc stearate (or alternative lubricant depending on manufacturer).
Film coating (typical): hypromellose, diacetylated monoglycerides, iron oxide red (E172), iron oxide black (E172) or yellow iron oxide (E172), titanium dioxide (E171), and printing ink.
The exact list of excipients may vary between manufacturers of generic sevelamer carbonate. Always read the patient information leaflet that accompanies your specific pack, particularly if you have known intolerances or allergies to excipients.
Appearance and Pack Sizes
Sevelamer Medical Valley 800 mg tablets are film-coated, oval or capsule-shaped, and typically off-white to pale cream or pale orange in colour, depending on the specific presentation. They are usually supplied in high-density polyethylene (HDPE) bottles with a child-resistant closure or in aluminium-aluminium blister strips. Common pack sizes include 30, 60, 100, 180, and 360 tablets. Not all pack sizes may be marketed in every country.
Marketing authorisation holder: Medical Valley Invest AB (or the locally authorised representative). For country-specific marketing information and the most current approved patient information leaflet, consult your national medicines regulator, your pharmacist, or the EMA public database.
Frequently Asked Questions About Sevelamer Medical Valley
Medical References and Sources
This article is based on current medical research and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- European Medicines Agency (EMA). Renvela (sevelamer carbonate) – Summary of Product Characteristics. Available at: ema.europa.eu/en/medicines/human/EPAR/renvela
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017). "KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD)." Kidney International Supplements, 7(1):1–59. DOI: 10.1016/j.kisu.2017.04.001
- Chertow GM, Burke SK, Raggi P (2002). "Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients (Treat to Goal)." Kidney International, 62(1):245–252. DOI: 10.1046/j.1523-1755.2002.00434.x
- Suki WN, Zabaneh R, Cangiano JL, et al. (2007). "Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients (DCOR)." Kidney International, 72(9):1130–1137. DOI: 10.1038/sj.ki.5002466
- Block GA, Raggi P, Bellasi A, et al. (2007). "Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients." Kidney International, 71(5):438–441. DOI: 10.1038/sj.ki.5002059
- Di Iorio B, Bellasi A, Russo D (2012). "Mortality in kidney disease patients treated with phosphate binders: a randomized study (INDEPENDENT)." Clinical Journal of the American Society of Nephrology, 7(3):487–493. DOI: 10.2215/CJN.03820411
- Patel L, Bernard LM, Elder GJ (2016). "Sevelamer versus calcium-based binders for treatment of hyperphosphatemia in CKD: a meta-analysis of randomized controlled trials." Clinical Journal of the American Society of Nephrology, 11(2):232–244. DOI: 10.2215/CJN.06800615
- Ruospo M, Palmer SC, Natale P, et al. (2018). "Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)." Cochrane Database of Systematic Reviews, 8:CD006023. DOI: 10.1002/14651858.CD006023.pub3
- Ketteler M, Block GA, Evenepoel P, et al. (2018). "Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters." Kidney International, 92(1):26–36. DOI: 10.1016/j.kint.2017.04.006
- World Health Organization (WHO). WHO Model List of Essential Medicines, 23rd List (2023). Geneva: WHO.
- British National Formulary (BNF). Sevelamer carbonate – Drug Monograph. Available at: bnf.nice.org.uk
- Food and Drug Administration (FDA). Renvela (sevelamer carbonate) – US Prescribing Information. Available at: accessdata.fda.gov
Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, comprising board-certified physicians with expertise in nephrology, clinical pharmacology, and internal medicine.
iMedic Medical Editorial Team
Specialists in Clinical Pharmacology
iMedic Medical Review Board
Independent medical expert panel
All content follows the GRADE evidence framework and is reviewed according to EMA, FDA, KDIGO, and ERA-EDTA guidelines. We maintain strict editorial independence with no pharmaceutical industry funding. Read our editorial standards